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It is not unusual for children to require dialysis for ﬂuid and electrolyte management after hematopoietic cell
transplantation (HCT). Previous studies have documented high mortality in childrenwho require dialysis after
HCT, but recent data are lacking. The purpose of this study was to compare the incidence of dialysis after
pediatric HCT and the survival of patients who received dialysis in 2 decades, 1990-1999 and 2000-2009.
A total of 1427 patients age <21 years who underwent a ﬁrst HCT at the University of Minnesota between
January 1990 and December 2009 were reviewed using prospectively collected data from the institutional
HCT database. The incidence of dialysis during the ﬁrst 100 days post-HCT and survival at 1 year post-HCT in
the 2 cohorts were determined. Comparisons between patients who did and did not require dialysis were
made using the c2 and Fisher exact tests as appropriate. Kaplan-Meier estimates and 95% conﬁdence intervals
for 1-year post-HCT overall survival were reported by dialysis group and compared using the log-rank test.
Predictors of overall survival among patients requiring dialysis were assessed using univariate and multi-
variate Cox regression analyses. The incidence of dialysis was not signiﬁcantly different in the 2 cohorts (8.2%
for 1990-1999 versus 8.9% for 2000-2009; P ¼ .6326). Patients requiring dialysis were signiﬁcantly more likely
to survive to or past 1 year in the 2000-2009 cohort compared with the 1990-1999 cohort (23% versus 11%;
P < .0001). Multivariate analyses found that older age at the time of HCT, primary disease type, pulmonary
hemorrhage, and HCT in 1990-1999 were associated with increased mortality in the dialyzed population. The
use of cyclosporine was associated with increased survival in the patients who received dialysis. Dialysis is an
important complication of pediatric HCT with an incidence that has remained constant over the last
2 decades. Survival was improved in the 2000-2009 cohort regardless of dialysis status. Despite a recent
signiﬁcant reduction in mortality in patients requiring dialysis, mortality remains higher in these patients
than in those who do not need dialysis.
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Hematopoietic cell transplantation (HCT) is a critical
therapy formany childrenwith life-threatening illnesses. The
indications for HCT continue to expand as more nonmalig-
nant diseases are added to the diagnoses considered [1].
With improved HLA typing, transplantation techniques, and
supportive care, survival continues to improve, and the focus
is shifting to identifying andminimizing acute and long-term
complications, including renal injury [2-4]. The risk of acute
kidney injury (AKI) in the early posttransplantation period is
estimated to range from25% to 50% [5]. In 1994, Lane et al. [6]
reported 77% mortality in pediatric patients who required
dialysis after HCT. Few studies since then have readdressed
the incidence and outcomes of dialysis in the pediatric HCT
population. Reliance on adult studies with extrapolation of
results has been necessary given the relative paucity of
pediatric-speciﬁc data. We undertook the present retro-
spective study to provide updated data on incidence and
outcomes for pediatric patients requiring dialysis in the HCTedgments on page 664.
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12.12.012associated with poor outcomes. Our goal was to provide
a framework for designing prospective studies examining
interventions and therapeutic approaches. To our knowl-
edge, this is the largest single-center study of pediatric
patients undergoing HCT and requiring dialysis reported to
date.PATIENTS AND METHODS
Patient Population
A total of 1431 consecutive patients age <21 years who underwent
a ﬁrst HCT at the University of Minnesota between January 1990 and
December 2009 were reviewed. Patients were identiﬁed from the University
of Minnesota bone marrow transplantation database. Four patients were
excluded from the analysis because of donor source (3 with a graft from
a twin sibling and 1with autologous cord blood). The 1427 patients included
in the analysis were grouped based onwhether or not they required dialysis
(peritoneal, hemodialysis, or continuous renal replacement therapy) during
the ﬁrst 100 days after HCT. Of these patients, 122 (8.5%) were conﬁrmed to
have required dialysis within this 100-day period; an extensive chart review
was performed to collect additional data for these patients.Statistical Methods
Patient and transplant characteristics were compared by group
(requiring dialysis and not requiring dialysis) using c2 and Fisher exact tests
as appropriate. These characteristics included sex, age at HCT (0-10 years
versus 11-21 years), year of transplantation (1990-1999 versus 2000-2009),
primary diagnosis (acute leukemia/aplastic anemia/chronic myelogenous
leukemia/Fanconi anemia/lymphoma/other nonmalignancies/solid tumors),
Figure 1. OS for all pediatric HCT recipients from day of transplantation to 1 year
posttransplantation by dialysis group (within 100 days of HCT) and decade.
Table 1
Demographic and Clinical Characteristics of Pediatric HCT Recipients
Requiring and Not Requiring Dialysis within 100 Days of Transplantation
No Dialysis Dialysis P Value
Total patients, n (%) 1305 122
Sex, n (%) .1857
Female 498 (38.16) 54 (44.26)
Male 807 (61.84) 68 (55.74)
Age group, n (%) .0200
0-10 years 834 (63.91) 65 (53.28)
11-21 years 471 (36.09) 57 (46.72)
Transplantation group, n (%) .6326
1990-1999 714 (54.71) 64 (52.46)
2000-2009 591 (45.29) 58 (47.54)
Diagnosis category, n (%) .0845
Acute leukemia 527 (40.38) 52 (42.62)
Aplastic anemia 77 (5.90) 4 (3.28)
Chronic myelogenous
leukemia
42 (3.22) 1 (0.82)
Fanconi anemia 107 (8.20) 17 (13.93)
Lymphoma 55 (4.21) 1 (0.82)
Other nonmalignancies 368 (28.20) 35 (28.69)
Solid tumors 129 (9.89) 12 (9.84)
Transplant type/matching,
n (%)
.1163
Autologous 230 (17.62) 13 (10.66)
Allogeneic, related 356 (27.28) 30 (24.59)
Allogeneic, unrelated 398 (30.50) 47 (38.52)
Cord blood 321 (24.60) 32 (26.23)
Use of total body irradiation,
n (%)
.8588
Yes 856 (65.59) 81 (66.39)
No 449 (34.41) 41 (33.61)
Use of cyclosporine, n (%) .0229
Yes 794 (60.84) 87 (71.31)
No 511 (39.16) 35 (28.69)
Initial dialysis mode, n (%) d
Continuous Renal
Replacement Therapy
3 (2.50)
Hemodialysis 91 (75.21)
Peritoneal 27 (22.50)
Missing 1
Interval from HCT to dialysis,
days, mean  SD
122 30.0 (25.6) d
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lated/cord blood), use of total body irradiation, and use of cyclosporine.
Kaplan-Meier estimates for 1-year post-HCT overall survival (OS) are
reported by dialysis group and compared using the log-rank test [7]. Event
times were calculated from the date of HCT to the date of death or censored
at 1 year for those who lived beyond 1 year post-HCT. OS was also compared
by treatment decade (1990-1999 versus 2000-2009) and dialysis group.
Predictors of OS were examined in the 122 patients who received
dialysis. For this analysis, event times were calculated from the date of ﬁrst
dialysis to the date of death or censored at 1 year for those who lived beyond
1 year. Univariate Cox regression models were initially used to explore all
variables. In addition to the previously mentioned variables, time from
transplantation to dialysis, use of pressors at the initiation of dialysis,
intubation status at initiation of dialysis, blood urea nitrogen (BUN) at
initiation of dialysis (<100 mg/dL versus >100 mg/dL), and percent weight
change from hospital admission to ﬁrst dialysis (<10% versus >10%) were
also examined as predictors of OS. Engraftment status (absolute neutrophil
count>500 for 3 days), pulmonary hemorrhage, and veno-occlusive disease
were incorporated as time-dependent covariates.
Finally, a multivariate Cox regression model was developed by including
all of the covariates with a P value <.15 in the univariate analyses. Hazard
ratios (HRs) and 95% conﬁdence intervals (CIs) were calculated. A P value
<.05 was considered to indicate statistical signiﬁcance.RESULTS
Patient characteristics by dialysis group are presented in
Table 1. Of the 1427 patients included in the study, 122 were
identiﬁed as requiring dialysis during the ﬁrst 100 days post-
HCT and conﬁrmed via medical chart review. The incidenceof dialysis was 8.2% for 1990-1999 and 8.9% for 2000-2009,
a non-statistically signiﬁcant difference (P ¼ .6326). Consid-
erable year-to-year variability was observed in the propor-
tion of pediatric HCT patients who required dialysis. There
was however no evidence of a linear increase or decrease
over time (P ¼ .7417). Patients age 11-21 years at the time of
HCT were more likely to require dialysis than those age 0-10
years (P ¼ .0200). Patients who received cyclosporine were
more likely to require dialysis (P ¼ .0229). No other variables
were found to be signiﬁcant, although disease category
approached statistical signiﬁcance (P ¼ .0845). The mean
time from HCT to dialysis in those who required dialysis was
30  25.6 days.
One-year OS was 71% (95% CI, 68%-73%) in patients who
did not require dialysis versus 15% (95% CI, 9%-22%) in those
who required dialysis (P < .0001). OS remained signiﬁcantly
higher in the patients who did not require dialysis even after
splitting by decade of HCT. One-year OS in patients under-
going HCT in 1990-1999 was 64% (95% CI, 61%-68%) in those
who did not require dialysis and 11% (95% CI, 5%-20%) in
those who required dialysis (P < .0001). In comparison,
1-year OS in patients who underwent HCT in 2000-2009 was
79% (95% CI, 76%-82%) in those who did not require
dialysis and 23% (95% CI, 13%-34%) in those who required
dialysis (P < .0001) (Figure 1). In patients requiring dialysis,
the likelihood of survival was signiﬁcantly greater in the
2000-2009 cohort compared with the 1990-1999 cohort
(23% versus 11%; P < .0001).
Predictors of OS at 1 year post-HCT in patients requiring
dialysis are listed in Table 2. Older patients (age 11-21 years)
were twice as likely to die than younger patients (age 0-10
years) (HR, 2.05, 95% CI, 1.39-3.03; P ¼ .0003). Patients
undergoing HCT in 2000-2009 had an approximately 40%
lower risk of death compared with who did so in 1990-1999
(HR, 0.63; 95% CI, 0.43-0.93; P ¼ .0210). The use of cyclo-
sporine reduced the risk of death by approximately 40% (HR,
0.60; 95% CI, 0.39-0.91; P¼ .0171). At the initiation of dialysis,
a BUN value of >100 mg/dL increased the probability of
death by approximately 50% (HR, 1.48; 95% CI, 0.98-2.22; P ¼
.0598). As the percent weight change increased between
admission and time of ﬁrst dialysis, there was a trend toward
decreased mortality (P ¼ .0927). Pulmonary hemorrhage
increased the risk of death by 85% (HR, 1.85; 95% CI, 1.20-
2.85; P ¼ .0053). No other variables examined showed
a signiﬁcant association with OS.
When those variables with a P value .15 were examined
in a multivariate model, many remained signiﬁcant (Table 3).
Older patients (11-21 years) were approximately 2.3 times
Table 2
Predictors of OS through 1 Year Postdialysis in Pediatric HCT Recipients
Requiring Dialysis within 100 Days of HCT, Univariate Cox Regression
Patients,
n
Deaths,
n
HR (95% CI) P Value
Total 122 104
Sex .1561
Female* 54 49 1.00
Male 68 55 0.76 (0.51-1.11)
Age group .0003
0-10 years* 65 50 1.00
11-21 years 57 54 2.05 (1.39-3.03)
Transplantation group .0210
1990-1999* 64 57 1.00
2000-2009 58 47 0.63 (0.43-0.93)
Diagnosis category .1219
Acute leukemia* 52 46 1.00
Aplastic anemia 4 4 1.85 (0.66-5.16)
Chronic myelogenous
leukemia
1 1 1.98 (0.27-14.51)
Fanconi anemia 17 17 1.67 (0.95-2.92)
Lymphoma 1 1 1.42 (0.19-10.35)
Other nonmalignancies 35 26 0.69 (0.43-1.12)
Solid tumors 12 9 0.82 (0.40-1.68)
Transplant type .4313
Autologous* 13 10 1.00
Allogeneic, related 30 26 1.01 (0.49-2.10)
Allogeneic, unrelated 47 42 1.22 (0.61-2.43)
Cord blood 32 26 0.80 (0.39-1.67)
Use of total body
irradiation
.1138
No* 41 31 1.00
Yes 81 73 1.41 (0.92-2.14)
Use of cyclosporine .0171
No* 35 32 1.00
Yes 87 72 0.60 (0.39-0.91)
Interval from HCT to
dialysis, days
.1139
0-30* 81 67 1.00
31-100 41 37 1.38 (0.93-2.07)
Use of pressors .3500
No* 64 53 1.00
Yes 56 49 1.20 (0.82-1.78)
Intubatation at time
of dialysis
.6540
No* 59 50 1.00
Yes 62 53 1.09 (0.74-1.61)
BUN, mg/dL .0598
<100* 46 36 1.00
100 75 67 1.48 (0.98-2.22)
Percent weight change .0927
<0* 8 7 1.00
0-10 30 28 0.77 (0.34-1.77)
>10 81 66 0.52 (0.24-1.14)
Time-dependent variables
Engraftment (ANC >500
for 3 days)
122 104 0.68 (0.40-1.14) .1417
Pulmonary hemorrhage 122 104 1.85 (1.20-2.85) .0053
Veno-occlusive disease 122 104 1.15 (0.78-1.71) .4840
ANC indicates absolute neutrophil count.
* Reference group.
Table 3
Predictors of OS through 1 Year Postdialysis in Pediatric HCT Recipients
Requiring Dialysis within 100 Days of HCT, Multivariate Cox Regression
Variable HR (95% CI) P Value
Age group .0249
0-10 years* 1.00
11-21 years 2.26 (1.11-4.61) .0034
Transplantation group
1990-1999* 1.00
2000-2009 0.47 (0.28-0.78)
Diagnosis category .0379
Acute leukemia* 1.00
Aplastic anemia 3.47 (1.03-11.70)
Chronic myelogenous leukemia 0.49 (0.05-4.45)
Fanconi anemia 2.46 (1.23-4.93)
Lymphoma 0.91 (0.11-7.55)
Other nonmalignancies 1.47 (0.63-3.45)
Solid tumors 0.70 (0.27-1.84)
Use of total body irradiation .7922
No* 1.00
Yes 0.91 (0.45-1.83)
Use of cyclosporine .0411
No* 1.00
Yes 0.48 (0.24-0.97)
Interval from HCT to dialysis, days .2956
0-30* 1.00
31-100 1.30 (0.79-2.14)
BUN, mg/dL .3487
<100* 1.00
100 1.27 (0.77-2.10)
Percent weight change .6100
<0* 1.00
0-10 0.62 (0.24-1.63)
>10 0.75 (0.27-2.06)
Time-dependent variables
Engraftment (ANC >500 for 3 days) 0.55 (0.29-1.03) .0627
Pulmonary hemorrhage 2.90 (1.75-4.80) <.0001
ANC indicates absolute neutrophil count.
* Reference group.
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2.26; 95% CI, 1.11-4.61; P ¼ .0249). Patients who underwent
HCT in 2000-2009 had an approximately 50% lower risk of
death compared with those who did so in 1990-1999 (HR,
0.47; 95% CI, 0.28-0.78; P ¼ .0034). Disease category was
signiﬁcantly related to OS (P ¼ .0379). In particular, patients
with Fanconi anemia or aplastic anemia were approximately
2.5 times (HR, 2.46; 95% CI, 1.23-4.93) and 3.5 times (HR,
3.47; 95% CI, 1.03-11.70) more likely to die, respectively, than
those with acute leukemia. The use of cyclosporine was
found to reduce the risk of death by approximately 50% (HR,
0.48; 95% CI, 0.24-0.97; P ¼ .0411). Pulmonary hemorrhagewas associated with an approximately 3-fold increase in
mortality (HR, 2.90; 95% CI, 1.75-4.80; P < .0001).
DISCUSSION
We have shown that the incidence of dialysis within the
ﬁrst 100 days after pediatric HCT has remained consistent
over the past 2 decades, at roughly 8%-9%. Although the
likelihood of survival has improved in both dialyzed and
nondialyzed patients, the former continue to exhibit a much
higher mortality rate. Thus, despite improvements in care
that have led to increased survival of pediatric HCT recipi-
ents, the need for dialysis remains a clinically important
problem, with a substantial impact on the success of HCT in
children.
A recent large retrospective study in adults undergoing
allogeneic HCT found a 5%-8% incidence of dialysis depend-
ing on the year of transplantation [4]. Those who underwent
HCT in 2003-2007 had a signiﬁcantly lower incidence of
dialysis than those who did so in 1993-1997. The use of
dialysis was evaluated through the ﬁrst 100 days post-
transplantation, and mortality not preceded by disease
relapse was assessed at day 200 and overall. Mortality in the
renal injury subgroup was not evaluated. In a study of
pediatric patients who underwent HCT at our institution
between 1978 and 1990, 5% (31 of 649) required dialysis [6].
The mean time to dialysis from HCT was 29  15 days in the
renal recovery group and 35  32 days in the no renal
recovery group. Only 3 patients survived to hospital
discharge, all of whom experienced renal recovery [6]. To our
knowledge, no large pediatric studies of dialysis after HCT
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pediatric patients found that the incidence of dialysis has
remained stable over the past 2 decades. The proportion of
patients who developed acute renal insufﬁciency but did not
progress on to dialysis was not examined in this study. In
retrospective pediatric studies, the reported incidence of
acute renal insufﬁciency has ranged from 25% to 50% [5,7,8].
In a prospective study of 66 children over a 2-year period,
Kist-van Holthe et al. [9] reported a 21% incidence of acute
renal insufﬁciency posttransplantation. None of the patients
in their cohort required dialysis.
In the present study, demographic and clinical factors
associated with an increased incidence of dialysis included
older age at time of HCTand use of cyclosporine as part of the
therapeutic regimen. Risk factors that have previously been
associated with the development of acute renal insufﬁciency
or the need for dialysis in HCT recipients include veno-
occlusive disease, nephrotoxic medications, previous renal
insufﬁciency, total body irradiation, and diagnosis requiring
transplantation [5-7,9,10].
Zager et al. [10], in 1989, recognized the signiﬁcant effect
of renal impairment on survival after HCT in adults. Doubling
of serum creatinine level was associated with a doubling of
mortality, and the need for dialysis was associated with
amortality rate of 84%. In previous pediatric studies, reported
mortality rates for children in the ﬁrst year post-HCT have
ranged from 9% to 33% [3,8,9], increasing to 77%-90% in those
who required dialysis [5,6]. In the present study, the drop in
1-year post-HCT mortality rate from 89% in the patients
requiring dialysis in the 1990-1999 cohort to 78% in those in
the 2000-2009 cohort is a statistically signiﬁcant decrease.
Our patients were categorized by the need for dialysis during
the ﬁrst 100 days post-HCT, and thus the values may under-
represent actual survival, given that patients who developed
a need for dialysis later in their course were analyzed in the
nondialysis group. The majority of cases of AKI will be
captured within 100 days post-HCT, however [11].
In HCT recipients requiring dialysis, Lane et al. [6] iden-
tiﬁed the use of multiple medications for blood pressure
support, hyperbilirubinemia, and weight gain of 10% of
baseline body weight at initiation of dialysis as factors
associated with persistent renal failure and mortality. In the
present study, greater age at time of HCT was associated with
increased incidence of dialysis and increased mortality if
dialysis was required, perhaps because older patients are
likely to have attempted a greater number of failed therapies
before advancing to HCT. In addition, younger patients are
more likely to undergo HCT for nonmalignant diseases,
which might modulate the impact of dialysis on survival.
We found that the diagnoses of Fanconi anemia and
aplastic anemia were associated with worse survival if dial-
ysis was required. Fanconi anemia is a multisystem disease
caused by an underlying defect in DNA repair. Abnormalities
of the genitourinary tract are present in approximately 30%
of patients with Fanconi anemia; structural defects, such as
hypoplastic/aplastic or ectopic/pelvic kidneys, are the most
common abnormalities [12]. Patients with Fanconi anemia
accounted for a higher proportion of the patients requiring
dialysis compared with those not requiring dialysis (13.93%
versus 8.20%; P ¼ .0315). Perhaps subclinical renal abnor-
malities accounted for the overrepresentation of Fanconi
anemia in the dialysis recipients. Why patients with Fanconi
anemia had worse outcomes than other patients requiring
dialysis remains unclear. Only 4 patients requiring dialysis
had aplastic anemia; all 4 died during the ﬁrst year post-HCT.Because of the small number of patients with aplastic
anemia, our statistical ﬁndings should be interpreted with
caution. Interestingly, patients with Fanconi anemia and
aplastic anemia who did not require dialysis had better OS
than patients with acute leukemia (Fanconi anemia: HR,
0.58; 95% CI, 0.37-0.91; aplastic anemia: HR, 0.54; 95% CI,
0.32-0.92). This suggests that disease-speciﬁc factors may
account for the increasedmortality in dialysis recipients with
Fanconi anemia and aplastic anemia.
We found that use of cyclosporine was associated with
a greater need for dialysis. The nephrotoxicity associated
with calcineurin inhibitors is well known, so this ﬁnding is
not surprising [13]. However, among patients who required
dialysis, those who received cyclosporine exhibited better OS
at 1-year post-HCT. It should be noted that for our analysis,
the use of cyclosporine was recorded as binary (yes/no).
Information regarding speciﬁc target levels was not ob-
tained. In our HCT program, it is common practice to
administer cyclosporine as a continuous infusion rather than
as intermittent boluses in patients with acute renal insufﬁ-
ciency. The improved OS of the dialysis recipients who
required cyclosporine may represent both decreased ﬂuctu-
ation of drug levels and a previously unknown protective
drug effect in this subpopulation.
Although not found to be statistically signiﬁcant in our
multivariate analyses, BUN level at initiation of dialysismight
be clinically relevant in this population. In adult intensive
care unit patients with sepsis, early initiation of dialysis, as
deﬁned by BUN <100 mg/dL at timing of renal replacement
therapy, was associated with improved survival [14]. The
inverse relationship of weight gain and survival in our study
population is of unclear etiology and is in contrast to previous
reports [6]. We did not analyze the speciﬁc indications for
initiation of dialysis in our population, and this relationship
might reﬂect individuals who required dialysis mainly for
ﬂuid overload complications versus AKI.
Dialysis remains a common complication of HCT in the
pediatric population. Over the past 2 decades, the incidence
of dialysis has remained consistent, whereas survival in
patients requiring dialysis has improved. The advances in
care that have led to improved survival in pediatric HCT
recipients have not reduced the risk of dialysis, however, and
outcomes remain far worse in patients who require dialysis
compared with those who do not. Large prospective
pediatric-speciﬁc studies are needed to identify factors that
result in impaired renal function and develop strategies to
reduce the need for dialysis in this population.
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